The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal

Abstract

To the Editor,

The publication by Daniele Orsc et al. [1] in Critical Care, titled "Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis," has significant clinical implications. This present study obtained two key findings that may complement their conclusions.

The primary outcome of this meta-analysis revealed a higher thromboembolic event risk associated with Andexanet alpha when analyzing controlled (RCT and PSM) studies. However, the authors did not perform trial sequential analysis (TSA), potentially leading to type I and type II errors and premature conclusions. To address this, TSA Viewer version 0.9.5.10 Beta was utilized to determine if published studies provided sufficient evidence for reliable conclusions. The two-sided type I error was set at 5%, and 80% power was selected to calculate the required information size (RIS). The control group incidence was determined through meta-analysis. Results from the TSA showed that the blue Z-curve crossed the conventional boundary but not the TSA boundary (Fig. 1). Moreover, the data failed to meet the required information size (RIS = 1717). Consequently, conventional meta-analysis may yield false-positive results. Additional trials are necessary to confirm the difference in thromboembolic events between the groups.

Fig. 1

Trial sequential analysis (TSA) for the rate of thromboembolic events. Blue Z curve stands for Z-values accumulated from the meta-analysis (combined relative risk). Pink dotted lines are indicative of conventional boundaries, whereas red solid lines stand for TSA boundaries. RIS, required information size

Full size image

In the analysis of all-cause short-term mortality in retrospective studies, the authors included the studies with varying follow-up periods, ranging from 7-day, 28-day, 30-day, and in-hospital mortality. This variability may introduce inaccuracies in meta-analysis results due to factors such as persistent treatment effects and disease deterioration, potentially leading to heterogeneity and compromising result interpretation and conclusion reliability. To address this, a subgroup analysis using Revman5.3 software was conducted on six studies [2,3,4,5,6,7] that reported 30-day mortality. Employing a fixed-effects model, the risk ratio (RR) for the Andexanet alpha group was 0.62 (95% CI 0.47–0.84) compared to four-factor prothrombin complex in retrospective studies, as shown in Fig. 2. This difference achieved statistical significance. The discrepancies between these findings and those of the original meta-analysis highlight the importance of considering distinct time points when evaluating mortality rates in critically ill patients. Therefore, additional high-quality RCTs are necessary for validation purposes.

Fig. 2

Forest plots for 30-day mortality in the retrospective studies

Full size image

Not applicable.

1. Orso D, Fonda F, Brussa A, Comisso I, Auci E, Sartori M, et al. Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis. Crit Care. 2024;28(1):221.

   Article PubMed PubMed Central Google Scholar

2. Siepen BM, Polymeris A, Shoamanesh A, Connolly S, Steiner T, Poli S, et al. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors—individual patient data analysis of ANNEXA-4 and TICH-NOAC. Int J Stroke. 2024;19(5):506–14.

   Article PubMed Google Scholar

3. Oh ES, Schulze P, Diaz F, Shah K, Rios J, Silverman ME. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage. Am J Emerg Med. 2023;64:74–7.

   Article PubMed Google Scholar

4. Vestal ML, Hodulik K, Mando-Vandrick J, James ML, Ortel TL, Fuller M, et al. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis. 2022;53(1):167–75.

   Article PubMed Google Scholar

5. Stevens VM, Trujillo TC, Kiser TH, MacLaren R, Reynolds PM, Mueller SW. Retrospective comparison of andexanet alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding. Clin Appl Thromb Hemost. 2021;27:10760296211039020.

   Article PubMed PubMed Central Google Scholar

6. Irizarry-Gatell VM, Bacchus MW, De Leo EK, Zhang Y, Lagasse CA, Khanna AY, et al. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage. Blood Coagul Fibrinolysis. 2024;35(3):94–100.

   Article PubMed Google Scholar

7. Huttner HB, Gerner ST, Kuramatsu JB, Connolly SJ, Beyer-Westendorf J, Demchuk AM, et al. Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care. Stroke. 2022;53(2):532–43.

   Article PubMed Google Scholar

Download references

None.

Authors and Affiliations

1. Department of Social Services, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning Province, China

   Tengfei Yang

2. Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning Province, China

   Bo Zhao

Authors

1. Tengfei YangView author publications

   You can also search for this author in PubMed Google Scholar

2. Bo ZhaoView author publications

   You can also search for this author in PubMed Google Scholar

Contributions

Tengfei Yang and Bo Zhao conceptualized the study, performed the literature research, and drafted the manuscript. Bo Zhao supervised the research, provided critical revisions, and contributed to the final manuscript. Both authors read and approved the final version of the manuscript for submission.

Corresponding author

Correspondence to Bo Zhao.

Ethics approval and consent to participate

Not applicable.

Competing interests

None.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Yang, T., Zhao, B. The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal. Crit Care 28, 373 (2024). https://doi.org/10.1186/s13054-024-05157-x

Download citation

• Received: 25 October 2024

• Accepted: 01 November 2024

• Published: 19 November 2024

• DOI: https://doi.org/10.1186/s13054-024-05157-x

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative